Endothelial growth factor receptor (EGFR) mutations are found in up to 40% to 50% of the Asian population, and the treatment landscape of NSCLC was dramatically changed by EGFR-TKIs as systemic and adjuvant treatment. Here, EGFR is linked to non-small cell lung carcinoma.